- Home
- SNT vs IBIO Comparison
SNT vs IBIO Comparison
Compare SNT & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNT | IBIO |
|---|---|---|
| Founded | 1965 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 72.2M |
| IPO Year | 2023 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SNT | IBIO |
|---|---|---|
| Price | $2.76 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 15.3K | ★ 888.9K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.54 | $0.56 |
| 52 Week High | $5.34 | $3.82 |
Technical Indicators
Market Signals| Indicator | SNT | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 53.80 |
| Support Level | $2.54 | $1.70 |
| Resistance Level | $2.90 | $2.29 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 36.11 | 71.77 |
Price Performance
Historical ComparisonAbout SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.